Birth defects, congenital abnormalities, and hereditary diseases are the most common causes of Chronic Kidney Disease in children. A recent study confirmed that suPAR (soluble urokinase plasminogen activator receptor) is a new potential biomarker for kidney progression in children. The results were confirmed in a pediatric study where analysis of chronic kidney disease(CKD) is different from that of adults. This can be the key to successfully predict Chronic Kidney Disease in children.
In this study 565 children aged between 1 to 16 with mild to moderate CKD were examined. At the entrance to the study, they assessed suPAR levels and at 6 months, separating groups into quartiles. CKD progression was characterized as the initiation of kidney replacement therapy (dialysis or transplantation) or a decrease in eGFR by more than 50 percent. Adjustments have been made to establish risk factors for CKD progression. Researchers discovered that patients in the lowest suPAR quartile reported a 54 percent faster development of CKD relative to those in the highest.
In the early stages of kidney disease, suPAR may be particularly useful “where existing biomarkers, such as serum creatinine, are the most ineffective. The efficacy of this biomarker is also assessed in children with moderate kidney failure, as well as those with normal kidney function at high risk of developing kidney disease, so diagnosis and treatment will occur as early as possible. Chronic Kidney Disease in children is
“We desperately need additional biomarkers to predict which patients are at most risk for progression so we can potentially intervene on these patients sooner, as well as adequately prepare our patients and their families for the prognosis of a potentially grave, life-long chronic illness,” said Darcy K. Weidemann, MD, MHS, a pediatric nephrologist at Children’s Mercy Kansas City, told Healio Nephrology.